Results 51 to 60 of about 86,629 (276)

Proteasome Inhibitor Bortezomib Suppresses Nuclear Factor-Kappa B Activation and Ameliorates Eye Inflammation in Experimental Autoimmune Uveitis

Mediators of Inflammation, 2015
Bortezomib is a proteasome inhibitor used for hematologic cancer treatment. Since it can suppress NF-κB activation, which is critical for the inflammatory process, bortezomib has been found to possess anti-inflammatory activity.
Sheng-Min Hsu, Chang-Hao Yang, Fang-Hsiu Shen, Shun-Hua Chen, Chia-Jhen Lin, Chi-Chang Shieh   +5 more
doaj   +1 more source

USP15 targets ALK3/BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling [PDF]

, 2014
Protein kinase ALK3/BMPR1A mediates bone morphogenetic protein (BMP) signalling through phosphorylation and activation of SMADs 1/5/8. SMAD6, a transcriptional target of BMP, negatively regulates the BMP pathway by recruiting E3 ubiquitin ligases and ...
Al-Salihi, Mazin A., Bruce, David, Cummins, Timothy D., Dingwell, Kevin S., Ewan, Richard, Herhaus, Lina, Macartney, Thomas, Sapkota, Gopal P., Smith, James C., Vogt, Janis, Wasmus, Lise, Weidlich, Simone   +11 more
core   +3 more sources

Meta‐analysis fails to show any correlation between protein abundance and ubiquitination changes

FEBS Open Bio, EarlyView.
We analyzed over 50 published proteomics datasets to explore the relationship between protein levels and ubiquitination changes across multiple experimental conditions and biological systems. Although ubiquitination is often associated with protein degradation, our analysis shows that changes in ubiquitination do not globally correlate with changes in ...
Nerea Osinalde, Unai Alduntzin, Gorka Prieto, Ugo Mayor   +3 more
wiley   +1 more source

Daratumumab Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Case Report

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune‐mediated neuropathy featuring progressive weakness, sensory deficits, and areflexia. While corticosteroids, intravenous immunoglobulin, and plasmapheresis are effective first‐line immunotherapies, a subset of patients remains treatment‐refractory.
Xueyu Zhang, Jianli Zhao, Xue Zhao, Xiaowei Hu, Zichun Xiao, Jie Wu, Xiaowen Li, Jing Xu, Yu‐Jing Li   +8 more
wiley   +1 more source

Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.

PLoS ONE, 2010
The proteasome inhibitor bortezomib represents an important advance in the treatment of multiple myeloma (MM). Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of ...
Feng Ge, Chuan-Le Xiao, Li-Jun Bi, Sheng-Ce Tao, Sheng Xiong, Xin-Feng Yin, Li-Ping Li, Chun-Hua Lu, Hai-Tao Jia, Qing-Yu He   +9 more
doaj   +1 more source

Automating Vascular Biology: An End‐to‐End Automated Workflow for High‐Throughput Blood Vessel‐on‐a‐Chip Production and Multi‐Site Validation

Advanced Healthcare Materials, EarlyView.
AngioPlate384 is a 384‐well open‐top platform that automates production of more than 100 miniaturized, perfusable blood vessels embedded in hydrogel and supported by stromal cells. Stromal‐endothelial co‐culture strengthens blood vessel barrier function and yields responses useful for translational planning. Scalable and automation‐ready, it suits drug
Dawn S. Y. Lin, Hanieh Mohammad Hashemi, Kimia Asadi Jozani, Anushree Chakravarty, Sonya Kouthouridis, Jessica Bonanno, Nicky Anvari, Shravanthi Rajasekar, Feng Zhang, Richard Y. Cheng, Narendra Kumar Singh, Luis Miguel Medina, Marc Durante, Yufang He, Boyang Zhang   +14 more
wiley   +1 more source

Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity

Case Reports in Cardiology, 2016
Bortezomib is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. Traditionally, bortezomib was thought to have little cardiovascular toxicity; however, there is increasing evidence that bortezomib can lead to cardiac ...
Sachin Diwadkar, Aarti A. Patel, Michael G. Fradley   +2 more
doaj   +1 more source

ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5

JCI Insight, 2022
The proteasome inhibitors (PIs) bortezomib and carfilzomib, which target proteasome 20S subunit beta 5 (PSMB5) in cells, are widely used in multiple myeloma (MM) treatment.
Yan Yang, Yuhan Gao, Jingcao Huang, Zhuang Yang, Hongmei Luo, Fangfang Wang, Juan Xu, Yushan Cui, Hong Ding, Zhimei Lin, Xinyu Zhai, Ying Qu, Li Zhang, Ting Liu, Lingqun Ye, Ting Niu, Yuhuan Zheng   +16 more
doaj   +1 more source

TRIM47 Regulates Energy Metabolism via Glycolytic Reprogramming to Drive Hepatocellular Carcinoma Progression and Represents an Efficient Therapeutic Target

Advanced Science, EarlyView.
This study identifies TRIM47 as a key driver of liver cancer progression by promoting glycolysis through ubiquitin‐mediated degradation of the gluconeogenic enzyme FBP1. TRIM47 enhances glucose uptake, lactate and ATP production, and tumor growth and metastasis.
Weijie Sun, Yihang Yuan, Qian Qiu, Kexuan Tan, Xutong Li, Haotian Li, Luyang Kang, Yuting Gu, Ziheng Zhang, Jiayu He, Jiali Li, Junjie Lin, Zihan Xie, Kexing Han, Jiabin Li, Yang Zhang, Ting Wu, Yufeng Gao   +17 more
wiley   +1 more source

Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma

Case Reports in Hematology, 2016
Bortezomib is a first-generation proteasome inhibitor used in the treatment of multiple myeloma (MM). A few reports have linked bortezomib exposure with the development of thrombotic microangiopathy (TMA).
Jan Van Keer, Michel Delforge, Daan Dierickx, Kathelijne Peerlinck, Evelyne Lerut, Ben Sprangers   +5 more
doaj   +1 more source